Treatment of coronary artery disease is a major health care problem across the entire word,
and the United States. Unfortunately, despite a number of medical advances, diagnostic
procedure, or epidemiological studies, the treatment of these patients remain complex, and
and at times frustrating. In fact, the COURAGE trial conducted in 50 centers across United
States and Canada documented that drug treatment, coronary interventions or both were not
effective solution in coronary artery diseases.
A novel approach has recently been developed, based on the critical role of the potassium (K)
content in red-blood-cell in myocardial oxygenation, since oxygen and K binding by hemoglobin
(red-blood-cell) occurs simultaneously in blood passing through the lungs, whereas in the
organs as the heart, the hemoglobin release both Oxygen and K ions.
This apparently simple mechanisms occurs in human blood in all individuals but could be
altered in subjects with acquired or hereditable defect in red-blood-cell K content, as in
hypertensives or CAD patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Carabobo
Collaborators:
Clinical Research Unit at the Instituto Docente de Urologia Northern Metropolitan Hospital Venezuelan Foundation of Heart Failure